• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » InVivo Therapeutics asks FDA for permission to run human trial

InVivo Therapeutics asks FDA for permission to run human trial

July 8, 2011 By MassDevice staff

InVivo Therapeutics

InVivo Therapeutics (OTC:NVIV) wants the FDA’s blessing for a human trial of its biopolymer scaffold to treat traumatic spinal cord injuries.

The Cambridge, Mass.-based biotech firm said it filed an investigational device exemption application with the federal watchdog agency seeking permission to run a 10-patient trial of the device. It’s designed to "protect and support spinal tissue and prevent secondary injury, including inflammation and glial scarring, following traumatic spinal cord injury," according to a press release.

The study would follow the patients for a year after implantation with the device at centers in Boston and Washington; the subjects will be sent to rehabilitation facilities following the implantation procedures. The study’s main endpoint is safety data; secondary endpoints include motor and sensory recovery, determined according to the American Spinal Injury Assn.’s impairment score.

"InVivo’s first regulatory submission for human testing is a major step forward in realizing the promise of our technology for spinal cord injury patients," CEO Frank Reynolds said in prepared remarks. "Our goal for this initial study is to safely minimize the secondary injury processes, thereby allowing the body to reorganize locally toward functional recovery through the spared healthy tissue. This process, known as neuroplasticity, may result in partial functional recovery."

It’s at least the second time Reynolds has touted an IDE application. In a December 2009 email, he wrote that InVivo believes the therapy "represents the most significant development in the history [of] spinal cord injury treatment."

"This is Huge!!” Reynolds wrote. In prepared remarks issued the same day, he said the company anticipated revenues from its first product to exceed the billion-dollar mark.

The InVivo implant is shaped by the implanting surgeon to conform to each patient’s spinal cord lesion and is designed to dissolve over about 12 weeks. The company is also working on an injectable hydrogel to carry therapeutics agents to the injury site without requiring invasive surgery.

Filed Under: Biotech, Food & Drug Administration (FDA), News Well, Spine Tagged With: InVivo Therapeutics

More recent news

  • Medtronic escapes $106.5M payment in Colibri TAVR patent suit after court overturns jury verdict
  • RadNet closes iCAD acquisition, expands AI breast‑imaging portfolio
  • Hyperfine reports first commercial sales of next-gen AI-powered Swoop
  • Stereotaxis announces $12.5M offering
  • Nuwellis ends clinical trial of its ultrafiltration tech for heart failure

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy